Markers to define ischemia: Are they ready for prime time use in patients with acute coronary syndromes?
- 31 Downloads
Optimal treatment of patients who present with chest pain is predicated on accurate identification of those patients with a cardiac etiology of their discomfort. Serial troponins and electrocardiograms are very sensitive for the detection of myocardial infarction but they are insensitive for the detection of ischemia. There are many analytes that are being actively evaluated for routine use to facilitate the identification of patients with myocardial ischemia. At present, only one assay is US Food and Drug Administration-approved for the exclusion of ischemia; many other analytes are under clinical evaluation and are briefly reviewed. At present, none of these analytes are yet appropriate for routine clinical use.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 2.Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA guidelines for the management of patients with unstable angina and non- ST segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2000, 36:970–1062. The current consensus document for the accepted evaluation and treatment of patients who present with ACS.PubMedCrossRefGoogle Scholar
- 5.Apple FS, Quist HE, Doyle PJ, et al.: Plasma 99th percentile reference limits for cardiac troponin and creatine kinase MB mass for use with European Society of Cardiology/American College of Cardiology consensus recommendations. Clin Chem 2003, 49:1331–1336. The overview of the best contemporary cutpoints to use for troponin testing.PubMedCrossRefGoogle Scholar
- 9.Myocardial infarction redefined: a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000, 36:959–969. Myocardial infarction redefined for the current diagnostic age; this is the current paradigm for marker diagnostics.Google Scholar
- 11.Jaffe AS: Testing the wrong hypothesis: the failure to recognize the limitations of troponin testing. J Am Coll Cardiol 2001, 38:999–1001. An excellent overview of the limitation of diagnostic assays. The issues raised here are critical for assessment of these relatively scantily evaluated markers of ischemia.PubMedCrossRefGoogle Scholar
- 12.McDonough JL, Labugger R, Van Eyk JE: Prepare to meet your markers: making the most of troponin degradation. In Markers in Cardiology: Current and Future Clinical Applications. Edited by Adams JE, Apple FS, Jaffe AS, Wu AHB. Armonk, NJ: Futura; 2001:13–21.Google Scholar
- 20.Singa MK, Roy D, Gaze DC, et al.: Role of “ischemia modified albumin,” a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary artery syndromes. Emerg Med J 2004, 21:29–34. This article is the best assessment yet of the only FDA-approved assay, IMA, for the exclusion of ischemia.CrossRefGoogle Scholar